newsfilter
← Latest News
PR Newswire·

Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital Experience

DUBLIN, Nov. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTC:MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies on real world outcomes of patients hospitalized with hepatorenal syndrome